Cover Image
市場調查報告書

血脂異常:開發平台分析

Dyslipidemia - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 232789
出版日期 內容資訊 英文 280 Pages
訂單完成後即時交付
價格
Back to Top
血脂異常:開發平台分析 Dyslipidemia - Pipeline Review, H1 2017
出版日期: 2017年03月22日 內容資訊: 英文 280 Pages
簡介

所謂血脂異常症,是血中的整體膽固醇值上升,或是「壞」低密度脂蛋白(LDL)膽固醇與三酸甘油酯(中性脂肪)增加,「好」高密度脂蛋白(HDL)膽固醇濃度下降的狀態。由於各式各樣的因素與原因,使血液中的脂質濃度發生異常。譬如,遺傳性原因、伙食、年齡和性、第二型糖尿病等。 血脂異常引起的一般症狀,有角膜混濁、角膜環、黃色瘤、平衡障礙、步行時小腿疼痛、暈眩等。

本報告提供血脂異常症的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關的開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新新聞和發表。

簡介

  • 調查範圍

血脂異常症 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關研究中的產品

治療藥開發作的企業

  • Acasti Pharma Inc.
  • Allergan Plc
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Arbutus Biopharma Corporation
  • Arisaph Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • AtheroNova Inc.
  • BASF SE
  • BCWorld Pharm Co. Ltd.
  • Cadila Pharmaceuticals Ltd.
  • Cardax Pharmaceuticals, Inc.
  • Catabasis Pharmaceuticals, Inc.
  • Cerenis Therapeutics Holding SA
  • Chong Kun Dang Pharmaceutical Corp.
  • CJ HealthCare Corp.
  • Connexios Life Sciences Pvt. Ltd.
  • CymaBay Therapeutics, Inc.
  • Daewoong Pharmaceutical Co., Ltd.
  • 第一三共
  • Debiopharm International S.A.
  • Eli Lilly and Company
  • Esperion Therapeutics, Inc.
  • Genfit SA
  • GlaxoSmithKline Plc
  • HanAll Biopharma Co., Ltd.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Huons Co., Ltd.
  • Hyundai Pharmaceutical Co., Ltd.
  • Innovent Biologics, Inc.
  • IPCA Laboratories Limited
  • Jeil Pharmaceutical Co., Ltd.
  • Jenrin Discovery, Inc.
  • JW Pharmaceutical Corporation
  • Kissei藥品工業
  • 祝詞製藥
  • 興和
  • Kymab Limited
  • LG Life Science LTD.
  • Lipicard Technologies Limited
  • Lotus Pharmaceutical Co., Ltd.
  • Matinas BioPharma Holdings, Inc.
  • Merck & Co., Inc.
  • Nimbus Therapeutics, LLC
  • Nippon Chemipher
  • Pfizer Inc.
  • Pharmena SA
  • Prometheon Pharma, LLC
  • Protalix BioTherapeutics, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sancilio & Company, Inc.
  • 武田藥品工業
  • Thetis Pharmaceuticals LLC
  • Torrent Pharmaceuticals Limited
  • Viking Therapeutics, Inc.
  • Yuhan Corporation
  • Zydus Cadila Healthcare Limited

治療藥的評估

  • 單劑產品
  • 組合產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (amlodipine besylate + atorvastatin calcium + valsartan)
  • (amlodipine besylate + rosuvastatin calcium + valsartan)
  • (atorvastatin calcium + choline fenofibrate)
  • (atorvastatin calcium + hydroxychloroquine sulfate)
  • (atorvastatin calcium + losartan potassium)
  • (atorvastatin calcium + metformin hydrochloride) XR
  • (candesartan + rosuvastatin calcium)
  • (ezetimibe + rosuvastatin calcium)
  • (gemigliptin + rosuvastatin calcium)
  • (metformin hydrochloride SR + rosuvastatin calcium)
  • (pitavastatin + valsartan)
  • 4655-K09
  • AEM-28
  • AEM-2802
  • AEM-2814
  • AHRO-001
  • ALN-AC3
  • ALN-ANG
  • AMG-899
  • anacetrapib
  • ARI-3037MO
  • AS-1708727
  • AZ-12260493
  • BCWPC-001
  • bempedoic acid
  • bezafibrate ER
  • BH-03004
  • BioE-1115
  • bococizumab
  • BSN-272
  • C-24
  • C-3
  • CAT-2000 系列
  • CAT-2003
  • CDR-267F018
  • CDX-085
  • centatin
  • CER-209
  • CKD-519
  • CNX-013B2
  • Debio-0930B
  • DF-461
  • DPR-212
  • DS-8312
  • DS-9001
  • DWJ-1330
  • DWJ-1351
  • elafibranor
  • etanercept biosimilar
  • gemcabene calcium
  • GSK-2041706
  • HCP-1105
  • HOB-071
  • HU-012
  • IBI-306
  • icosabutate
  • IONIS-ANGPTL3LRx
  • ISIS-APOCIIILRx
  • JD-2000 系列
  • JD-5000 系列
  • JD-5006
  • JD-5037
  • JD-6000 系列
  • JLP-1302
  • JLP-1401
  • K-312
  • K-877
  • KT-6971
  • KTA-439
  • KY-1020
  • 白氨酸 + Niacin
  • LP-071
  • LT-5421
  • LT-5423
  • MAT-9001
  • MBX-8025
  • NC-2400
  • ND-630
  • ND-654
  • NKPL-66
  • 血脂異常症、動脈粥狀硬化性心血管疾病用寡核苷酸
  • 歐米加-3-羧酸
  • peroxibrate
  • PF-06427878
  • PF-06815345
  • pitabasutachin CR
  • 血脂異常症用HMG-CoA 還原酵素阻礙蛋白質
  • 血脂異常症用組換形式ApoE4
  • REGN-1001
  • saroglitazar
  • SC-401
  • 肥胖、血脂異常症、第二型糖尿病用Diacylglycerol Acyltransferase抑制劑1
  • 肥胖、血脂異常症、第二型糖尿病用Diacylglycerol Acyltransferase抑制劑2
  • 血脂異常症用小分子
  • 高甘油三酯血症用小分子
  • 第二型糖尿病、血脂異常症用小分子
  • 血脂異常症用脂蛋白解脂酵素活性小分子
  • 血脂異常症用甲狀腺荷爾蒙受體β 促效劑
  • 血脂異常症用farunesoidoX受體拮抗劑
  • 代謝障礙TRIP-Br2 抑制劑
  • 血脂異常症用、用高甘油三酯血症小分子
  • 血脂異常症、肥胖症用 DGAT-1抑制劑
  • 血脂異常症用 內皮層解脂酵素抑制劑
  • SPX-100
  • SPX-8522876
  • 循環系統疾病、消化疾病、代謝障礙、感染疾病用合成肽
  • TKMApoC-3
  • TP-101
  • TP-452
  • TRC-210258
  • TRIA-662
  • VK-0214
  • VK-2809
  • volanesorsen sodium
  • YH-22189
  • ZLN-005
  • ZLN-024
  • ZYH-7

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9091IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H1 2017, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape.

Dyslipidemia is defined as elevation of the total cholesterol, the "bad" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood such as genetic predisposition, diet, age and gender, type II diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness and confusion.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyslipidemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Dyslipidemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyslipidemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 17, 19, 14, 4, 41 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 13 and 4 molecules, respectively.

Dyslipidemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dyslipidemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Dyslipidemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dyslipidemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dyslipidemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dyslipidemia (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dyslipidemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dyslipidemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 6
  • List of Figures 8
  • Introduction 10
  • Global Markets Direct Report Coverage 10
  • Dyslipidemia - Overview 11
  • Dyslipidemia - Therapeutics Development 12
  • Pipeline Overview 12
  • Pipeline by Companies 13
  • Pipeline by Universities/Institutes 18
  • Products under Development by Companies 19
  • Products under Development by Universities/Institutes 25
  • Dyslipidemia - Therapeutics Assessment 26
  • Assessment by Target 26
  • Assessment by Mechanism of Action 30
  • Assessment by Route of Administration 34
  • Assessment by Molecule Type 36
  • Dyslipidemia - Companies Involved in Therapeutics Development 38
  • Acasti Pharma Inc 38
  • Akcea Therapeutics Inc 38
  • Allergan Plc 39
  • Amgen Inc 39
  • Arisaph Pharmaceuticals Inc 40
  • AstraZeneca Plc 40
  • BASF SE 41
  • BCWorld Pharm Co Ltd 41
  • BioRestorative Therapies Inc 42
  • Boryung Pharmaceutical Co Ltd 42
  • Cadila Pharmaceuticals Ltd 43
  • Cardax Inc 43
  • Catabasis Pharmaceuticals Inc 44
  • Celon Pharma SA 44
  • Cerenis Therapeutics Holding SA 45
  • Chong Kun Dang Pharmaceutical Corp 45
  • CJ HealthCare Corp 46
  • Connexios Life Sciences Pvt Ltd 46
  • CymaBay Therapeutics Inc 47
  • Daewoong Pharmaceutical Co Ltd 47
  • Daiichi Sankyo Company Ltd 48
  • Eli Lilly and Company 48
  • Esperion Therapeutics Inc 49
  • Gemphire Therapeutics Inc 49
  • Gilead Sciences Inc 50
  • GlaxoSmithKline Plc 50
  • Golden Biotechnology Corp 51
  • HanAll Biopharma Co Ltd 51
  • Hanmi Pharmaceuticals Co Ltd 52
  • Huons Co Ltd 52
  • Hyundai Pharmaceutical Co Ltd 53
  • Innovent Biologics Inc 53
  • IPCA Laboratories Ltd 54
  • Jeil Pharmaceutical Co Ltd 54
  • Jenrin Discovery Inc 55
  • JW Pharmaceutical Corp 55
  • Kissei Pharmaceutical Co Ltd 56
  • Kotobuki Pharmaceutical Co Ltd 56
  • Kowa Company Ltd 57
  • Kuhnil Pharmaceutical Co Ltd 57
  • Kyorin Pharmaceutical Co Ltd 58
  • Lipicard Technologies Ltd 58
  • Lipigon Pharmaceuticals AB 59
  • LipimetiX Development Inc 59
  • Lotus Pharmaceutical Co Ltd 60
  • Matinas BioPharma Holdings Inc 60
  • Merck & Co Inc 61
  • Nippon Chemiphar Co Ltd 61
  • Omeros Corp 62
  • Pfizer Inc 62
  • Pharmena SA 63
  • Protalix BioTherapeutics Inc 63
  • Regeneron Pharmaceuticals Inc 64
  • Samjin Pharmaceutical Co Ltd 64
  • Sancilio & Company Inc 65
  • Takeda Pharmaceutical Company Ltd 65
  • Tasly Pharmaceutical Group Co Ltd 66
  • Torrent Pharmaceuticals Ltd 66
  • Yuhan Corp 67
  • Zydus Cadila Healthcare Ltd 67
  • Dyslipidemia - Drug Profiles 68
  • (amlodipine besylate + fimasartan + rosuvastatin calcium) - Drug Profile 68
  • (amlodipine besylate + olmesartan medoxomil) + rosuvastatin calcium - Drug Profile 69
  • (amlodipine besylate + rosuvastatin calcium + valsartan) - Drug Profile 70
  • (amlodipine besylate + rosuvastatin calcium) - Drug Profile 71
  • (amlodipine besylate + valsartan)+ atorvastatin calcium - Drug Profile 72
  • (amlodipine maleate + rosuvastatin calcium + telmisartan) - Drug Profile 73
  • (atorvastatin calcium + choline fenofibrate) - Drug Profile 74
  • (atorvastatin calcium + hydroxychloroquine sulfate) - Drug Profile 75
  • (atorvastatin calcium + metformin hydrochloride XR) - Drug Profile 76
  • (atorvastatin calcium IR + losartan potassium DR) - Drug Profile 77
  • (candesartan cilexetil + rosuvastatin calcium) - Drug Profile 78
  • (metformin hydrochloride SR + rosuvastatin calcium) - Drug Profile 79
  • (metformin hydrochloride SR + rosuvastatin calcium) - Drug Profile 80
  • (nebivolol hydrochloride + rosuvastatin calcium) - Drug Profile 81
  • (pitavastatin + valsartan) - Drug Profile 82
  • 4655-K09 - Drug Profile 83
  • AC-261066 - Drug Profile 84
  • AEM-28 - Drug Profile 85
  • AEM-2802 - Drug Profile 87
  • AEM-2814 - Drug Profile 88
  • ALN-AC3 - Drug Profile 89
  • ALN-ANG - Drug Profile 90
  • AMG-899 - Drug Profile 91
  • anacetrapib - Drug Profile 93
  • Antibody to Inhibit ANGPTL4 for Hypertriglyceridemia - Drug Profile 95
  • antroquinonol - Drug Profile 96
  • ARGX-116 - Drug Profile 98
  • ARI-3037MO - Drug Profile 99
  • bempedoic acid - Drug Profile 101
  • bezafibrate SR - Drug Profile 113
  • BioE-1115 - Drug Profile 115
  • BKC-007 - Drug Profile 116
  • BSN-272 - Drug Profile 117
  • C-3 - Drug Profile 118
  • CAT-2000 Series - Drug Profile 119
  • CAT-2003 - Drug Profile 120
  • CDR-267F018 - Drug Profile 123
  • CDX-085 - Drug Profile 124
  • centatin - Drug Profile 127
  • CER-209 - Drug Profile 128
  • CKD-519 - Drug Profile 129
  • CNX-013B2 - Drug Profile 131
  • DF-461 - Drug Profile 132
  • Drugs to Inhibit Sortilin for Hypercholesterolemia - Drug Profile 133
  • DS-9001 - Drug Profile 134
  • DWJ-1330 - Drug Profile 136
  • etanercept biosimilar - Drug Profile 137
  • evinacumab - Drug Profile 139
  • gemcabene calcium - Drug Profile 141
  • GSK-2041706 - Drug Profile 145
  • HCP-1105 - Drug Profile 146
  • HOB-071 - Drug Profile 147
  • HU-012 - Drug Profile 148
  • IBI-306 - Drug Profile 149
  • icosabutate - Drug Profile 150
  • IMMH-007 - Drug Profile 152
  • IONIS-ANGPTL3LRx - Drug Profile 153
  • IONIS-APOCIIILRX - Drug Profile 155
  • JD-2000 Series - Drug Profile 156
  • JD-5000 Series - Drug Profile 157
  • JD-5006 - Drug Profile 158
  • JD-5037 - Drug Profile 159
  • JD-6000 Series - Drug Profile 160
  • JS-002 - Drug Profile 161
  • K-312 - Drug Profile 162
  • KI-1107 - Drug Profile 163
  • KKM-1201 - Drug Profile 164
  • KT-6971 - Drug Profile 165
  • KTA-439 - Drug Profile 166
  • leucine + niacin - Drug Profile 167
  • liothyronine sodium - Drug Profile 168
  • LP-071 - Drug Profile 169
  • LT-5421 - Drug Profile 170
  • LT-5423 - Drug Profile 171
  • LTPO-3FA - Drug Profile 172
  • LY-3202328 - Drug Profile 173
  • MAT-9001 - Drug Profile 174
  • metformin hydrochloride + rosuvastatin calcium - Drug Profile 176
  • MN-002 - Drug Profile 177
  • NC-2400 - Drug Profile 179
  • ND-630 - Drug Profile 180
  • ND-654 - Drug Profile 182
  • NKPL-66 - Drug Profile 185
  • Oligonucleotide for Hyperlipidemia and Atherosclerosis - Drug Profile 190
  • omega-3-carboxylic acids - Drug Profile 191
  • pemafibrate - Drug Profile 196
  • peroxibrate - Drug Profile 199
  • PF-06427878 - Drug Profile 200
  • Protein for Dislipidemia, Obesity and Type 2 Diabetes - Drug Profile 201
  • Recombinant ApoE4 for Dyslipidemia - Drug Profile 202
  • REGN-1001 - Drug Profile 203
  • saroglitazar - Drug Profile 204
  • SC-401 - Drug Profile 207
  • seladelpar - Drug Profile 208
  • SJP-1603 - Drug Profile 212
  • Small Molecule 1 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type 2 Diabetes - Drug Profile 213
  • Small Molecule 2 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type 2 Diabetes - Drug Profile 214
  • Small Molecule for Atherosclerosis and Hyperlipidemia - Drug Profile 215
  • Small Molecule for Cardiovascular and Metabolic Diseases - Drug Profile 216
  • Small Molecule for Hypertriglyceridaemia - Drug Profile 217
  • Small Molecule to Activate Lipoprotein Lipase for Dyslipidemia - Drug Profile 218
  • Small Molecule to Activate Lipoprotein Lipase for Dyslipidemia - Drug Profile 219
  • Small Molecule to Agonize TR-Beta for Dyslipidemia - Drug Profile 220
  • Small Molecule to Antagonize Farnesoid X Receptor for Dyslipidemia - Drug Profile 221
  • Small Molecule to Inhibit DGAT-2 for Dyslipidemia and Non-Alcoholic Steatohepatitis - Drug Profile 222
  • Small Molecule to Inhibit HSL for Dyslipidemia - Drug Profile 223
  • Small Molecules to Inhibit Endothelial Lipase for Dyslipidemia - Drug Profile 224
  • Small Molecules to Inhibit FABP1 for Hyperlipidemia and Fatty Liver Disease - Drug Profile 225
  • Small Molecules to Target GPR146 for Metabolic Disorders - Drug Profile 226
  • SPX-8522876 - Drug Profile 227
  • Stem Cell Therapy for Hypertension, Hyperlipidemia, Obesity and Type 2 Diabetes - Drug Profile 228
  • Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease - Drug Profile 230
  • Synthetic Peptides for Dyslipidemic and Vascular Disorders - Drug Profile 231
  • TRC-210258 - Drug Profile 232
  • TRIA-662 - Drug Profile 233
  • TSL-1516 - Drug Profile 235
  • volanesorsen sodium - Drug Profile 236
  • ZLN-005 - Drug Profile 243
  • ZLN-024 - Drug Profile 244
  • ZYH-7 - Drug Profile 245
  • Dyslipidemia - Dormant Projects 246
  • Dyslipidemia - Discontinued Products 255
  • Dyslipidemia - Product Development Milestones 259
  • Featured News & Press Releases 259
  • Appendix 271
  • Methodology 271
  • Coverage 271
  • Secondary Research 271
  • Primary Research 271
  • Expert Panel Validation 271
  • Contact Us 271
  • Disclaimer 272

List of Tables

  • Number of Products under Development for Dyslipidemia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Dyslipidemia - Pipeline by Acasti Pharma Inc, H1 2017
  • Dyslipidemia - Pipeline by Akcea Therapeutics Inc, H1 2017
  • Dyslipidemia - Pipeline by Allergan Plc, H1 2017
  • Dyslipidemia - Pipeline by Amgen Inc, H1 2017
  • Dyslipidemia - Pipeline by Arisaph Pharmaceuticals Inc, H1 2017
  • Dyslipidemia - Pipeline by AstraZeneca Plc, H1 2017
  • Dyslipidemia - Pipeline by BASF SE, H1 2017
  • Dyslipidemia - Pipeline by BCWorld Pharm Co Ltd, H1 2017
  • Dyslipidemia - Pipeline by BioRestorative Therapies Inc, H1 2017
  • Dyslipidemia - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017
  • Dyslipidemia - Pipeline by Cadila Pharmaceuticals Ltd, H1 2017
  • Dyslipidemia - Pipeline by Cardax Inc, H1 2017
  • Dyslipidemia - Pipeline by Catabasis Pharmaceuticals Inc, H1 2017
  • Dyslipidemia - Pipeline by Celon Pharma SA, H1 2017
  • Dyslipidemia - Pipeline by Cerenis Therapeutics Holding SA, H1 2017
  • Dyslipidemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
  • Dyslipidemia - Pipeline by CJ HealthCare Corp, H1 2017
  • Dyslipidemia - Pipeline by Connexios Life Sciences Pvt Ltd, H1 2017
  • Dyslipidemia - Pipeline by CymaBay Therapeutics Inc, H1 2017
  • Dyslipidemia - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
  • Dyslipidemia - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Dyslipidemia - Pipeline by Eli Lilly and Company, H1 2017
  • Dyslipidemia - Pipeline by Esperion Therapeutics Inc, H1 2017
  • Dyslipidemia - Pipeline by Gemphire Therapeutics Inc, H1 2017
  • Dyslipidemia - Pipeline by Gilead Sciences Inc, H1 2017
  • Dyslipidemia - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Dyslipidemia - Pipeline by Golden Biotechnology Corp, H1 2017
  • Dyslipidemia - Pipeline by HanAll Biopharma Co Ltd, H1 2017
  • Dyslipidemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
  • Dyslipidemia - Pipeline by Huons Co Ltd, H1 2017
  • Dyslipidemia - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017
  • Dyslipidemia - Pipeline by Innovent Biologics Inc, H1 2017
  • Dyslipidemia - Pipeline by IPCA Laboratories Ltd, H1 2017
  • Dyslipidemia - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017
  • Dyslipidemia - Pipeline by Jenrin Discovery Inc, H1 2017
  • Dyslipidemia - Pipeline by JW Pharmaceutical Corp, H1 2017
  • Dyslipidemia - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017
  • Dyslipidemia - Pipeline by Kotobuki Pharmaceutical Co Ltd, H1 2017
  • Dyslipidemia - Pipeline by Kowa Company Ltd, H1 2017
  • Dyslipidemia - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2017
  • Dyslipidemia - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
  • Dyslipidemia - Pipeline by Lipicard Technologies Ltd, H1 2017
  • Dyslipidemia - Pipeline by Lipigon Pharmaceuticals AB, H1 2017
  • Dyslipidemia - Pipeline by LipimetiX Development Inc, H1 2017
  • Dyslipidemia - Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017
  • Dyslipidemia - Pipeline by Matinas BioPharma Holdings Inc, H1 2017
  • Dyslipidemia - Pipeline by Merck & Co Inc, H1 2017
  • Dyslipidemia - Pipeline by Nippon Chemiphar Co Ltd, H1 2017
  • Dyslipidemia - Pipeline by Omeros Corp, H1 2017
  • Dyslipidemia - Pipeline by Pfizer Inc, H1 2017
  • Dyslipidemia - Pipeline by Pharmena SA, H1 2017
  • Dyslipidemia - Pipeline by Protalix BioTherapeutics Inc, H1 2017
  • Dyslipidemia - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
  • Dyslipidemia - Pipeline by Samjin Pharmaceutical Co Ltd, H1 2017
  • Dyslipidemia - Pipeline by Sancilio & Company Inc, H1 2017
  • Dyslipidemia - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Dyslipidemia - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017
  • Dyslipidemia - Pipeline by Torrent Pharmaceuticals Ltd, H1 2017
  • Dyslipidemia - Pipeline by Yuhan Corp, H1 2017
  • Dyslipidemia - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
  • Dyslipidemia - Dormant Projects, H1 2017
  • Dyslipidemia - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Dyslipidemia - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Dyslipidemia - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Dyslipidemia - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Dyslipidemia - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Dyslipidemia - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Dyslipidemia - Dormant Projects, H1 2017 (Contd..7), H1 2017
  • Dyslipidemia - Dormant Projects, H1 2017 (Contd..8), H1 2017
  • Dyslipidemia - Discontinued Products, H1 2017
  • Dyslipidemia - Discontinued Products, H1 2017 (Contd..1), H1 2017
  • Dyslipidemia - Discontinued Products, H1 2017 (Contd..2), H1 2017
  • Dyslipidemia - Discontinued Products, H1 2017 (Contd..3), H1 2017

List of Figures

  • Number of Products under Development for Dyslipidemia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top